Combination therapy as first-line treatment for hypertension

American Journal of Cardiovascular Drugs

Volumn 9, Issue 1, 2009, Pages 1-6

  Crawford, Michael H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMILORIDE PLUS HYDROCHLOROTHIAZIDE; AMLODIPINE; AMLODIPINE PLUS BENAZEPRIL; AMLODIPINE PLUS OLMESARTAN; AMLODIPINE PLUS VALSARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL PLUS CHLORTALIDONE; AVALIDE; BENAZEPRIL; BENDROFLUMETHIAZIDE PLUS NADOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL FUMARATE PLUS HYDROCHLOROTHIAZIDE; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN HEXETIL; CAPTOPRIL PLUS HYDROCHLOROTHIAZIDE; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; ENALAPRIL MALEATE PLUS FELODIPINE; ENALAPRIL PLUS HYDROCHLOROTHIAZIDE; EPROSARTAN; HYDRALAZINE; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS LISINOPRIL; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; HYDROCHLOROTHIAZIDE PLUS PROPRANOLOL; HYDROCHLOROTHIAZIDE PLUS QUINAPRIL; HYDROCHLOROTHIAZIDE PLUS TIMOLOL MALEATE; HYDROCHLOROTHIAZIDE PLUS TRIAMTERENE; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; METOPROLOL TARTRATE; MOEXIPRIL; SPIRONOLACTONE; TELMISARTAN; THIAZIDE DIURETIC AGENT; TIMOLIDE; TRANDOLAPRIL PLUS VERAPAMIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; UNIRETIC; VALSARTAN; VASODILATOR AGENT;

ACUTE CORONARY SYNDROME; BLOOD PRESSURE MONITORING; BRADYCARDIA; COST BENEFIT ANALYSIS; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; GLYCEMIC CONTROL; HIGH RISK PATIENT; HUMAN; HYPERTENSION; NOTE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PILL; PRACTICE GUIDELINE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; STROKE; VASCULAR DISEASE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DIURETICS; DRUG COMBINATIONS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; PATIENT COMPLIANCE; RENIN-ANGIOTENSIN SYSTEM;

EID: 59349097678     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03256590     Document Type: Note

References (51)

1. Ezzati M, Lopez AD, Rodgers A, et al. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360 (9343): 1347-60
2. Lopez AD, Mathers CD, Ezzati M, et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006; 367 (9524): 1747-57
3. Dickinson HO, Mason JM, Nicolson DJ, et al. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. J Hypertens 2006; 24 (2): 215-33
4. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001; 344 (1): 3-10
5. The Trials of Hypertension Prevention Collaborative Research Group. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II. Arch Intern Med 1997; 157 (6): 657-67
6. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000; 356 (9246): 1955-64
7. Turnbull F, Neal B, Ninomiya T, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008; 336 (7653): 1121-3
8. Staessen JA, Gasowski J, Wang JG, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000; 355 (9207): 865-72
9. Gueyffier F, Boutitie F, Boissel JP, et al. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men: a meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators. Ann Intern Med 1997; 126 (10): 761-7
10. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362 (9395): 1527-35
11. Williams MJA, Low CJS, Wilkins GT, et al. Randomized comparison of the effects of nicardipine and esmolol on coronary artery wall stress: implications for the risk of plaque rupture. Heart 2000; 84: 377-82
12. Staessen JA, Fogard R, Lutgarde T, et al. Randomized double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757-64
13. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based upon valsartan or amlodipine: the VALUE randomized trial. Lancet 2004; 363: 2022-31
14. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42 (6): 1206-52
15. The Kidney Disease Outcome Quality Initiative (KDOQI) clinical practice guidelines for chronic kidney disease and diabetes. Am J Kidney Dis 2007; 48 (2 Suppl. 2): S12-154
16. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008; 32 Suppl. 1: S1-S201
17. American Diabetes Association. American Diabetes Association clinical practice recommendations 2007. Diabetes Care 2007; 30 Suppl. 1: 51-104
18. Canetero OA, Oparil S. Essential Hypertension: part I. Definition and etiology. Circulation 2000; 101: 329-35
19. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28 (12): 1462-536
20. Black HR, Elliott WJ, Grandits G, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003; 289 (16): 2073-82
21. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) 2002; 4 (6): 393-404
22. Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326 (7404): 1427
23. Gerbino PP, Shoheiber O. Adherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agents. Am J Health Syst Pharm 2007; 64 (12): 1279-83
24. Waeber B, Burnier M, Brunner HR. Compliance with antihypertensive therapy. Clin Exp Hypertens 1999; 21 (5-6): 973-85
25. Laragh JH, Sealey JE. Relevance of the plasma renin hormonal control system that regulates blood pressure and sodium balance for correctly treating hypertension and for evaluating ALLHAT. Am J Hypertens 2003; 16 (5 Pt 1): 407-15
26. AIRE study investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) study. Lancet 1993; 342: 821-8
27. Turnbull F, Neal B, Algert C, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005; 165 (12): 1410-9
28. Brewster LM, van Montfrans GA, Kleijnen J. Systematic review: antihypertensive drug therapy in black patients. Ann Intern Med 2004; 141 (8): 614-27
29. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288 (23): 2981-97
30. Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs 2002; 62 (3): 443-62
31. Ambrosioni E, Borghi C, Costa FV. Captopril and hydrochlorothiazide: rationale for their combinations. Br J Clin Pharmacol 1987; 23 Suppl. 1: 43-50S
32. Chrysant S. Using Fixed-dose combination therapies to achieve blood pressure goals. Clin Drug Invest 2008; 28: 713-34
33. Ram CV. Antihypertensive efficacy of angiotensin receptor blockers in combination with hydrochlorothiazide: a review of the factorial-design studies. J Clin Hypertens 2004; 6: 569-77
34. De la Sierra A, Gil-Extremera B, Calvo C, et al. Comparison of the antihypertensive effects of the fixed dose combination enalapril 10 mg/nitrendipine 20 mg vs losartan 50 mg/hydrochlorothiazide 12.5 mg, assessed by 24-h ambulatory blood pressure monitoring, in essential hypertensive patients. J Hum Hypertens 2004; 18: 215-22
35. Elliott WJ, Montoro R, Smith D, et al. Comparison of two strategies for intensifying antihypertensive treatment: low-dose combination (enalapril + felodipine ER) versus increased dose of monotherapy (enalapril). LEVEL (Lexxel vs Enalapril) Study Group. Am J Hypertens 1999; 12 (7): 691-6
36. Karlberg BE, Andrup M, Oden A. Efficacy and safety of a new long-acting drug combination, trandolapril/verapamil as compared to monotherapy in primary hypertension. Swedish TARKA trialists. Blood Press 2000; 9 (2-3): 140-5
37. Smith TR, Philipp T, Vaisse B, et al. Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies. J Clin Hypertens (Greenwich) 2007; 9 (5): 355-64
38. Dahlof B, Ever B, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regime of amlodipine adding perindopril as required versus atenolol adding bendroylumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA) a multicenter randomized controlled trial. Lancet 2005; 366: 895-906
39. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359; 23: 2417-28
40. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290: 2805-16
41. Bellet M, Sassaus P, Guyene T, et al. Converting enzyme inhibition buffers the counter-regulatory response to acute administration of nicardipine. J Clin Pharmacol 1987; 24: 465-72
42. Kjeldsen SE, Jamerson JA, Bakris GL, et al. Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study. Blood Press 2008; 17: 7-17
43. Black HR, Elliott WJ, Grandits G, et al. Principle results of the controlled onset verapamil investigation of cardiovascular endpoints (CONVINCE) trial. JAMA 2003; 289: 2073-82
44. Black HR, Elliott WJ, Neaton JD, et al. Baseline characteristics and early blood pressure control in the CONVINCE trial. Hypertension 2001; 37: 12-8
45. Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120: 713-9
46. Smith TR, Philipp T, Vaisse B, et al. Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies. J Clin Hypertens (Greenwich) 2007; 9 (5): 355-64
47. Fernandez R, Puig JG, Rodriguez-Perez JC, et al. Effect of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patients with albuminuria: a randomised, double-blind study. J Hum Hypertens 2001; 15: 849-56
48. Bakris G, Molitch M, Hewkin A, et al. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006; 29: 2592-7
49. Weir MR, Bakris GL. Combination therapy with renin-angiotensin- aldosterone receptor blockers for hypertension: how far have we come? J Clin Hypertens 2008; 10: 146-52
50. Rabbani A, Alexander C. Out-of-pocket and total costs of fixed-dose combination antihypertensives and their components. Am J Hypertens 2008; 21: 509-13
51. Arredondo A. Out-of-pocket costs to users: medicine options for hypertension. Am J Hypertens 2008; 21: 492